期刊文献+

基于毛细管电泳法人血清的代谢组学研究

Study on human serum metabonomics with capillary electrophoresis
下载PDF
导出
摘要 目的本文以毛细管电泳(CE)技术对肿瘤患者血清代谢组学规律的研究。方法非涂层石英毛细管柱(57cm×75μm);分离电压30kv,毛细管柱温20℃,检测波长为200nm,毛细管电泳背景电解质:40mmol/L硼砂+5mmol/LMSDS,pill0.0;进样量为5s×0.5psi;图谱中数据用32Karat软件导出,导出数据经SIMCA—P12.0的PLS.DA法进行模式识别分析。结果血清中各代谢组分被完全分离,日内和日间精密度(RSD)分别为0.18%~4.25%和11.14%-4.65%:健康组血清和肿瘤组血清全组分分析能较好聚类区分;提取出11个高贡献率的代谢物并能对健康组和肿瘤组聚类区分;采用该方法获得的代谢物变化与同时检测出CA125值的变化相对一致。结论代谢组学的CE法检测和研究可能成为肿瘤早期诊断潜在标志物研究的又一种方法,所体现的关联代谢组分可为进一步肿瘤的早期诊断生物标志物的研究提供一定的基础依据。 Objective To study the metabonomics of tumor patient serum with capillary electrophoresis (CE). Methods Capillary zone electrophoresis (CZE) was used with non-coated fused silica capillary column(57cm×75μm), separation voltage of 30kV at 20℃, and with running buffer of 40mmol/L borax-5mmol/L SDS(pH 10.0) with injection time of 5 second at 0.5 psi and detection wavelength of 200nm. The data was exported with 32Karat and analyzed by SIMCA-P 12.0 with PLS-DA method. Results The serum metabolic components were completely separated, the intraday and interday precision (RSD) are 0.18%-4.25% and 1.14%-4.65%. Healthy serum and tumor serum were got well clustering distinguished. 11 metabolites with high contribution rate were extracted and it was well clustering distinguished between healthy serum and tumor serum with the 11 metabolites; the change of metabolites and simultaneous CA125 were relatively consistent. Conclusion The metabonomics with CE may become another method for early diagnosis of cancer potential biomarkers, and the relative metabolic components reflected can provide some basic evidence for further early diagnosis of cancer biomarker research.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2013年第9期684-687,695,共5页 Chinese Journal of Antibiotics
基金 四川省重点科技支撑项目(2011SZ131 11-13 10.0)
关键词 毛细管电泳 代谢组学 人血清 肿瘤 Capillary electrophoresis Metabonomics Human serum Tumor
  • 相关文献

参考文献9

  • 1Hanahan D, Weinberg R A. The hallmarks of cancer[J]. Cell, 2000, 100(1): 57-70.
  • 2Schmidt C. Metabolomics takes its place as latest up-and- coming "omic" science[J]. J Natl Cancer Inst, 2004, 96(10): 732-734.
  • 3Serkova N J, Spratlin J L, Eckhardt S G. NMR-based metabolomics: Translational application and treatment of cancer. Current Opinion in Molecular Therapeutics[J]. Mol Ther, 2007, 9(6): 572-585.
  • 4Yang J, Xu G, Zheng Y. Strategy for metabolomics research based on high-performance liquid chromatography and liquid chromatography coupled with tandem mass spectrometry [J]. ChromatogrA, 2005, 1084(1-2): 214-221.
  • 5Wu H, Xue R, Dong L, et al. Metabolic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry[J]. Anal Chim Acta, 2009, 648(1): 98-104.
  • 6Wang S F, Yang P, Zhao X P. Amino acid profile determination in the urine of bladder cancer patients by CE-MS with on-line pH-mediated stacking and pattern recognition[J]. ChromatogrA, 2009, 70(9-10): 1479-1484.
  • 7Szymanska E, Markuszewski M J, Capron X, et al. Increasing conclusiveness of metabonomic studies by chem- inforrnatic preprocessing of capillary electrophoretic data on urinary nucleoside profiles[J]. Pharm Biomed Anal, 2007, 43(2): 413-420.
  • 8Tablack P S, ehouli J N, Iesporek S, et al. Mass spectrometry based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline -mors[J]. Cancer Res, 2006, 66(22): 10795-10804.
  • 9王新宇,叶菁,冯素文,吕卫国,万小云,谢幸.血清CA125水平测定在预测卵巢上皮性癌复发和预后中的价值[J].中华妇产科杂志,2010,45(11):813-816. 被引量:28

二级参考文献9

  • 1陈艳,叶大风,谢幸.血清CA125测定在上皮性卵巢癌病情监测中的作用[J].国外医学(计划生育分册),2005,24(2):90-94. 被引量:6
  • 2Ozols RF,Bundy BN,Greer BE,et al.Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer:a Gynecologic Oncology Group study.J Clin Oncol,2003,21:3194-3200.
  • 3NCCN.NCCN clinical practice guidelines in oncology,ovarian cancer v.1.2010[EB/OL].[2010-6-10].http://www.nccn.org.
  • 4Kim HS,Kim JW,Chung HH,et al.Disease confined within the ovary and smaller amount of ascites are good prognostic factors for survival of patients with squamous cell carcinoma arising from mature cystic teratoma of the ovary:a case series in Korea and review of the published reports.J Obstet Gynaecol Res,2009,35:99-105.
  • 5Bast RC Jr,Klug TL,St John E,et al.A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.N Engl J Med,1983,309:883-887.
  • 6Jacobs I,Bast RC Jr.The CA 125 tumour-associated antigen:a review of the literature.Hum Reprod,1989,4:1-12.
  • 7Gemer O,Lurian M,Gdalevich M,et al.A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer.Eur J Surg Oncol,2005,31:1006-1010.
  • 8Kim HS,Park NH,Chung HH,et al.Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.Onkologie,2008,31:315-320.
  • 9Rocconi RP,Matthews KS,Kemper MK,et al.The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.Gynecol Oncol,2009,114:242-245.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部